Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?

Basit Öğe Kaydı
dc.authoridduran, Ayse Ocak/0000-0002-1703-726X
dc.authoriduçar, Mahmut/0000-0002-3311-6152
dc.authoridUysal, Mukremin/0000-0002-8524-0665
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridDuzkopru, Yakup/0000-0003-2314-5870
dc.authoridKaplan, Muhammet Ali/0000-0003-0882-0524
dc.authorwosidBerk, Veli/IXE-0017-2023
dc.authorwosidduran, Ayse Ocak/ABA-7090-2021
dc.authorwosiduçar, Mahmut/KBQ-8934-2024
dc.authorwosidÖZASLAN, ERSİN/V-3556-2017
dc.authorwosidUysal, Mukremin/B-8956-2014
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidDuzkopru, Yakup/GLT-1944-2022
dc.contributor.authorBozkurt, Oktay
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorDuzkopru, Yakup
dc.contributor.authorUysal, Mukremin
dc.contributor.authorKaraca, Halit
dc.contributor.authorBerk, Veli
dc.date.accessioned2024-06-12T11:07:29Z
dc.date.available2024-06-12T11:07:29Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAlthough there has been an increase in overall and progression-free survival with the use of novel targeted therapies in metastatic renal cell carcinoma (mRCC) in recent times, predictive markers to determine which patients would benefit from tyrosine kinase inhibitor therapies are needed. The late recurrence might be a predictive marker for response to sunitinib treatment in patients with mRCC. Background: We investigated the clinicopathological features in patients with recurrent renal cell carcinoma (RCC) within 5 years or more than 5 years after nephrectomy and determined predictors of overall survival (OS) and progression-free survival (PFS) after disease recurrence in the administration of first-line sunitinib in the treatment of metastatic RCC (mRCC). Patients and Methods: In this study we enrolled 86 Turkish patients with mRCC who received sunitinib. Univariate analyses were performed using the log rank test. Results: Fifty-six patients (65%) were diagnosed with disease recurrence within 5 years after radical nephrectomy (early recurrence) and 30 patients (35%) were diagnosed with recurrence more than 5 years after radical nephrectomy (late recurrence). Fuhrman grade was statistically significantly different between the 2 groups (P = .013). The late recurrence patients were significantly associated with the Memorial Sloan Kettering Cancer Center favorable risk group compared with patients with early recurrence (p = .001). There was a statistically significant correlation between recurrence time and the rate of objective remission (ORR) (the late recurrence group vs. the early recurrence group: 43.3% vs. 14.3%, respectively; P = .004). From the time of disease recurrence, the median OS was 42.0 (95% confidence interval [CI], 24.4-59.5) months in the late recurrence group, and 16 (95% CI, 11.5-20.4) months in the early recurrence group (P = .001). Median PFS was 8(95% CI, 4.05-11.9) months in the early recurrence group, and 20 (95% CI, 14.8-25.1) months in the late recurrence group (P <= .001). Conclusion: The study demonstrated a potential prognostic value of late recurrence in terms of PFS, OS, and ORR. (C) 2015 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.clgc.2015.07.005
dc.identifier.endpage554en_US
dc.identifier.issn1558-7673
dc.identifier.issn1938-0682
dc.identifier.issue6en_US
dc.identifier.pmid26320661en_US
dc.identifier.scopus2-s2.0-84947864292en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage548en_US
dc.identifier.urihttps://doi.org/10.1016/j.clgc.2015.07.005
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22065
dc.identifier.volume13en_US
dc.identifier.wosWOS:000365633700009en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCig Media Group, Lpen_US
dc.relation.ispartofClinical Genitourinary Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLate Recurrenceen_US
dc.subjectPrognostic Factoren_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectSunitiniben_US
dc.subjectSurvivalen_US
dc.subjectPrognostic-Factorsen_US
dc.subjectTargeted Therapyen_US
dc.subjectInterferon-Alphaen_US
dc.subjectSurvivalen_US
dc.subjectNephrectomyen_US
dc.subjectTemsirolimusen_US
dc.subjectMulticenteren_US
dc.subjectValidationen_US
dc.subjectManagementen_US
dc.subjectInhibitoren_US
dc.titleIs Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu